This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
Patients with PD duration between 1 month and 3 months.
Patients aged between 18 and 75 years.
Voluntary signing of informed consent.
Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.
Pregnant and lactating women.
Patients with type 1 diabetes mellitus.
Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.
Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT > 120 IU/L, and other clinically confirmed severe liver diseases.
Crossover
Dapagliflozin
DrugDapagliflozin10MG, PO once daily
Change in 24 urine volume
The total amount of urine excreted over a 24-hour period. The patient's urine output was measured continuously for 2 days, and the average volume was calculated, with the unit being millilitres.
Change in renal Kt/Vurea
A measure used in peritoneal dialysis therapy to assess adequacy, representing the renal clearance of urea (K) over time (t) normalized to body water volume (V).
Change in BNP（Brain natriuretic peptide）
Concentration of serum BNP which could assess cardiac function.
Change in EF%
The ejection fraction (EF%) value was measured using echocardiography by the hospital's ultrasound department, with all ultrasound examinations conducted by two attending physicians.
Change in ultrafiltration
The total amount of water removed from the body through dialysis each day.
Click on the lead sponsor to view all of their trials.
